Skip to main content
Top
Published in: Medical Oncology 1/2011

01-12-2011 | Original Paper

Potential role of serum level of soluble CD44 and IFN-γ in B-cell chronic lymphocytic leukemia

Authors: Nervana Samy, M. D. Abd El-Maksoud, T. E. Mousa, Hatem A. El-Mezayen, Mohamed Shaalan

Published in: Medical Oncology | Special Issue 1/2011

Login to get access

Abstract

Evidence indicates that the slowly expanding population of B cells that characterizes chronic lymphocytic leukemia (CLL) results primarily from defects in responses to cytokines. We evaluated the prognostic value of soluble CD44 and IFN-γ in B-cell chronic lymphocytic leukemia (B-CLL) and analyzed their source and regulation secretion in B-CLL clones in vitro. Levels of soluble CD44 standard (sCD44s) and IFN-γ were analyzed by enzyme-linked immunosorbent assay. B-CLL cells were separated and stimulated in vitro for the detection of both markers. Serum levels of sCD44s and IFN-γ were significantly elevated in patients with B-CLL in comparison with normal persons. Elevated levels of sCD44s and IFN-γ were associated with an advanced disease as reflected by increased values as stage progress. In B-CLL, sCD44s as well as IFN-γ was shed from leukemia cells as shown by in vitro cultures. Stimulation of B-CLL clones results in a proliferation-associated increased secretion of sCD44s and IFN-γ. B-CLL clones from advanced-stage patients are characterized by an increased capacity for proliferation and production of both markers in comparison with early-stage patients. Our present results suggest that sCD44 and IFN-γ may be of major importance in the pathogenesis of B-CLL, and inhibition of the effects of sCD44 and IFN-γ could be a potential therapeutic strategy.
Literature
1.
go back to reference Zhu Q, Tan DC, Samuel M, Chan ES, Linn YC. Fludarabine in comparison to alkylator-based regimen as induction therapy for chronic lymphocytic leukemia: a systematic review and meta-analysis. Leuk Lymphoma. 2004;45:2239–45.PubMedCrossRef Zhu Q, Tan DC, Samuel M, Chan ES, Linn YC. Fludarabine in comparison to alkylator-based regimen as induction therapy for chronic lymphocytic leukemia: a systematic review and meta-analysis. Leuk Lymphoma. 2004;45:2239–45.PubMedCrossRef
2.
go back to reference Naor D, Shulamit B, Zahalka MA, Sionov RV. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Canc Biol. 2008;18:260–7.CrossRef Naor D, Shulamit B, Zahalka MA, Sionov RV. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Canc Biol. 2008;18:260–7.CrossRef
3.
go back to reference Wielenga VJ, Heider KH, Offerhaus GJ, Adolf GR, van den Berg FM, Ponta H, Herrlich P, Pals ST. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res. 1993;53:4754–6.PubMed Wielenga VJ, Heider KH, Offerhaus GJ, Adolf GR, van den Berg FM, Ponta H, Herrlich P, Pals ST. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res. 1993;53:4754–6.PubMed
4.
go back to reference Taylor DD, Gercel-Taylor C, Gall SA. Expression and shedding of CD44 variant isoforms in patients with gynecologic malignancies. J Soc Gynecol Invest. 1996;3:289–94.CrossRef Taylor DD, Gercel-Taylor C, Gall SA. Expression and shedding of CD44 variant isoforms in patients with gynecologic malignancies. J Soc Gynecol Invest. 1996;3:289–94.CrossRef
5.
go back to reference Guo YJ, Liu G, Wang X, Jin D, Wu M, Ma J, Sy MS. Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res. 1994;54:422–6.PubMed Guo YJ, Liu G, Wang X, Jin D, Wu M, Ma J, Sy MS. Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res. 1994;54:422–6.PubMed
6.
go back to reference Kan M, Kanayama H, Naruo S, Tsuji M, Kojima K, Kurokawa Y, Kagawa S. Serological evaluation of soluble CD44 in renal cancer. Jpn J Cancer Res. 1996;87:1191–4.PubMedCrossRef Kan M, Kanayama H, Naruo S, Tsuji M, Kojima K, Kurokawa Y, Kagawa S. Serological evaluation of soluble CD44 in renal cancer. Jpn J Cancer Res. 1996;87:1191–4.PubMedCrossRef
7.
go back to reference Rossi G, Marroni P, Paganuzzi M, Mauro FR, Tenca C, Zarcone D, Velardi A, Molica S, Grossi CE. Increased serum levels of soluble CD44 standard, but not of variant isoforms v5 and v6, in B cell chronic lymphocytic leukemia. Leukemia. 1997;11:134–41.PubMedCrossRef Rossi G, Marroni P, Paganuzzi M, Mauro FR, Tenca C, Zarcone D, Velardi A, Molica S, Grossi CE. Increased serum levels of soluble CD44 standard, but not of variant isoforms v5 and v6, in B cell chronic lymphocytic leukemia. Leukemia. 1997;11:134–41.PubMedCrossRef
8.
go back to reference Nasu H, Hibi N, Ohyashiki JH, Hara A, Kubono K, Tsukada Y, Ando K, Iwama H, Hayashi S, Yahata N, Toyama K, Ohyashiki K. Serum soluble CD44 levels for monitoring disease states in acute leukemia and myelodysplastic syndromes. Int J Oncol. 1998;13:525–30.PubMed Nasu H, Hibi N, Ohyashiki JH, Hara A, Kubono K, Tsukada Y, Ando K, Iwama H, Hayashi S, Yahata N, Toyama K, Ohyashiki K. Serum soluble CD44 levels for monitoring disease states in acute leukemia and myelodysplastic syndromes. Int J Oncol. 1998;13:525–30.PubMed
9.
go back to reference Zaki MH, Douglas RS, Patten N, et al. Resistance of CLL B cells to apoptosis: involvement of type 1 (interferon-gamma) cytokine pathways. Blood. 1998;92:4177. Zaki MH, Douglas RS, Patten N, et al. Resistance of CLL B cells to apoptosis: involvement of type 1 (interferon-gamma) cytokine pathways. Blood. 1998;92:4177.
10.
go back to reference Chronic lymphocytic leukemia: recommendations for diagnosis, staging and response criteria. In: Proceedings of the international workshop on chronic lymphocytic leukemia. Ann Int Med 1989;110:236–8. Chronic lymphocytic leukemia: recommendations for diagnosis, staging and response criteria. In: Proceedings of the international workshop on chronic lymphocytic leukemia. Ann Int Med 1989;110:236–8.
11.
go back to reference Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML. A revised European–American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361–92.PubMed Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML. A revised European–American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361–92.PubMed
12.
go back to reference Rai KR. A critical analysis of staging in CLL. In: Gale RP, Rai KR, editors. Chronic lymphocytic leukemia: recent progress and future directions, vol. 59. New York: Alan R Liss; 1987. p. 253–64. Rai KR. A critical analysis of staging in CLL. In: Gale RP, Rai KR, editors. Chronic lymphocytic leukemia: recent progress and future directions, vol. 59. New York: Alan R Liss; 1987. p. 253–64.
13.
go back to reference Jilani I, Wei C, Bekele BN. Soluble syndecan-1(sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia. Int J Lab Hematol. 2008;12:234–9. Jilani I, Wei C, Bekele BN. Soluble syndecan-1(sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia. Int J Lab Hematol. 2008;12:234–9.
14.
go back to reference Sasaki K, Niitsu N. Elevated serum levels of soluble CD44variant 6 are correlated with shorter survival in aggressive non-hodgkin’s lymphoma. Eur J Haematol. 2000;65:195–202.PubMedCrossRef Sasaki K, Niitsu N. Elevated serum levels of soluble CD44variant 6 are correlated with shorter survival in aggressive non-hodgkin’s lymphoma. Eur J Haematol. 2000;65:195–202.PubMedCrossRef
15.
go back to reference ch Law CL, Gordon KA, Collier J, Klussman K, McEarchern JA, Cerveny CG, Mixan BJ, Lee WP, Lin Z, Valdez P, Wahl AF, Grewal IS. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res. 2005;65:8331–8.CrossRef ch Law CL, Gordon KA, Collier J, Klussman K, McEarchern JA, Cerveny CG, Mixan BJ, Lee WP, Lin Z, Valdez P, Wahl AF, Grewal IS. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res. 2005;65:8331–8.CrossRef
16.
go back to reference Eisterer W, Bechter O, Soderberg O, Nilsson K, Terol M, Greil R, Thaler J, Gunthert U, Reinhard SE. Elevated levels of soluble CD44 are associated with advanced disease and in vitro proliferation of neoplastic lymphocytes in B-cell chronic lymphocytic leukaemia. Leuk Res. 2004;28:1043–51.PubMedCrossRef Eisterer W, Bechter O, Soderberg O, Nilsson K, Terol M, Greil R, Thaler J, Gunthert U, Reinhard SE. Elevated levels of soluble CD44 are associated with advanced disease and in vitro proliferation of neoplastic lymphocytes in B-cell chronic lymphocytic leukaemia. Leuk Res. 2004;28:1043–51.PubMedCrossRef
17.
go back to reference Luqman M, Klabunde S, Lin K, Georgakis GV, Cherukuri A, Holash J, Goldbeck C, Xu X, Kadel EE III, Lee SH, Aukerman SL, Jallal B, Aziz N, Weng WK, Wierda W, O’Brien S, Younes A. The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood. 2008;112:711–20.PubMedCrossRef Luqman M, Klabunde S, Lin K, Georgakis GV, Cherukuri A, Holash J, Goldbeck C, Xu X, Kadel EE III, Lee SH, Aukerman SL, Jallal B, Aziz N, Weng WK, Wierda W, O’Brien S, Younes A. The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood. 2008;112:711–20.PubMedCrossRef
18.
go back to reference Molica S, Vitelli G, Levato D, Giannar Celli D, Candlfo GM. Elevated serum levels of soluble CD44 can identify subgroup of patients with early B-cell chronic lymphocytic leukemia. Who are at high risk of disease progression? Cancer. 2001;92(4):713–9.PubMedCrossRef Molica S, Vitelli G, Levato D, Giannar Celli D, Candlfo GM. Elevated serum levels of soluble CD44 can identify subgroup of patients with early B-cell chronic lymphocytic leukemia. Who are at high risk of disease progression? Cancer. 2001;92(4):713–9.PubMedCrossRef
19.
go back to reference Lapalombella R, Yu B, Triantafillou G, Liu Q, Butchar JP, Lozanski G. Ramanunni aronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. 2006;24:5343–9.CrossRef Lapalombella R, Yu B, Triantafillou G, Liu Q, Butchar JP, Lozanski G. Ramanunni aronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. 2006;24:5343–9.CrossRef
20.
go back to reference Fowler MT, Prentice AG. Modulation of apoptosis with cytokines in B-cells chronic lymphocytic leukemia. Leuk Lymphoma. 1996;21(5–6):369–77.CrossRef Fowler MT, Prentice AG. Modulation of apoptosis with cytokines in B-cells chronic lymphocytic leukemia. Leuk Lymphoma. 1996;21(5–6):369–77.CrossRef
21.
go back to reference Zaki M, Douglas R, Patten N, Bachinsky M, Lamb R, Nowell P, Moore J. Disruption of the IFN-g cytokine network in chronic lymphocytic leukemia contributes to resistance of leukemic B cells to apoptosis. Leuk Res. 2000;24:611–21.PubMedCrossRef Zaki M, Douglas R, Patten N, Bachinsky M, Lamb R, Nowell P, Moore J. Disruption of the IFN-g cytokine network in chronic lymphocytic leukemia contributes to resistance of leukemic B cells to apoptosis. Leuk Res. 2000;24:611–21.PubMedCrossRef
22.
go back to reference Jewell AP, Lydyard PM, Worman CP, Giles FJ, Goldstone AH. Growth factors can protect B-chronic lymphocytic leukemia cells against programmed cell death without stimulating proliferation. Leuk Lymph. 1995;18:159–66.CrossRef Jewell AP, Lydyard PM, Worman CP, Giles FJ, Goldstone AH. Growth factors can protect B-chronic lymphocytic leukemia cells against programmed cell death without stimulating proliferation. Leuk Lymph. 1995;18:159–66.CrossRef
23.
go back to reference Molica S, De Rossi G, Luciani M, Levato D. Prognostic features and therapeutical approaches in B-cell chronic lymphocytic leukemia: an update. Haematologica. 1995;80:176–9.PubMed Molica S, De Rossi G, Luciani M, Levato D. Prognostic features and therapeutical approaches in B-cell chronic lymphocytic leukemia: an update. Haematologica. 1995;80:176–9.PubMed
24.
go back to reference Pestka S. The interferon receptors. Semin Oncol. 1997;9:S9. Pestka S. The interferon receptors. Semin Oncol. 1997;9:S9.
Metadata
Title
Potential role of serum level of soluble CD44 and IFN-γ in B-cell chronic lymphocytic leukemia
Authors
Nervana Samy
M. D. Abd El-Maksoud
T. E. Mousa
Hatem A. El-Mezayen
Mohamed Shaalan
Publication date
01-12-2011
Publisher
Springer US
Published in
Medical Oncology / Issue Special Issue 1/2011
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9661-6

Other articles of this Special Issue 1/2011

Medical Oncology 1/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.